Status:
COMPLETED
A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese
Lead Sponsor:
Pfizer
Conditions:
Obesity
Eligibility:
All Genders
18-64 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: * how the study medicine, danug...
Eligibility Criteria
Inclusion
- Key
- 18 to \< 65 years of age
- Body mass index (BMI) of ≥25.0-45.4 kg/m2; and a total body weight \>50 kg (110 lb)
- Key
Exclusion
- Evidence or history of any clinically significant medical conditions or laboratory abnormality
- Any condition possibly affecting drug absorption
- Known intolerance/hypersensitivity to a GLP-1R agonist and/or known hypersensitivity or contraindication to atorvastatin (Cohort 1 and 3 participants) or rosuvastatin (Cohort 2 and 4 participants)
Key Trial Info
Start Date :
August 28 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 14 2025
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT06567327
Start Date
August 28 2024
End Date
April 14 2025
Last Update
August 6 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Anaheim Clinical Trials, LLC
Anaheim, California, United States, 92801
2
Qps - Mra, Llc.
South Miami, Florida, United States, 33143
3
Qps-Mra, Llc
South Miami, Florida, United States, 33143